Trials / Unknown
UnknownNCT00877747
Early Chemotherapy Intensification in Interim-Positron Emission Tomography (PET) Positive Hodgkin Lymphoma
Early Chemotherapy Intensification With BEACOPP in High-risk, Interim-PET Positive Advanced-stage Hodgkin Lymphoma:a GITIL Retrospective Multicenter Clinical Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 160 (actual)
- Sponsor
- Ospedale Santa Croce-Carle Cuneo · Academic / Other
- Sex
- All
- Age
- 16 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Early interim-PET after two courses of chemotherapy is a powerful outcome predictor in advanced-stage Hodgkin Lymphoma (HL) patients treated with adriamycin (doxorubicin), bleomycin, vinblastine and dacarbazine (ABVD). Two-year Progression Free Survival of PET-2 positive patients is only 12%, but the optimal treatment for this patient subset is still unknown. From January 2006 GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) suggested an early intensification of chemotherapy with BEACOPP \[Bleomycin, Etoposide, Adriamycin (doxorubicin), Cyclophosphamide, Oncovin (vincristine), Procarbazine, and Prednisone\](4 escalated + 4 baseline cycles) for all the HL patients with a positive PET-2 after 2 ABVD courses. The investigators retrospectively recorded and analyzed these data in order to evaluate if this strategy could be of benefit for this subset of patients.
Conditions
Timeline
- Start date
- 2006-01-01
- Primary completion
- 2014-11-01
- Completion
- 2015-10-01
- First posted
- 2009-04-08
- Last updated
- 2015-10-19
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT00877747. Inclusion in this directory is not an endorsement.